UBS downgraded Catamaran (CTRX) to Neutral saying the stock new fully reflects the UnitedHealth (UNH) takeover deal terms. UnitedHealth management in recent meetings expressed confidence that its pending $61.50 per share purchase of Catamaran will still close in the second half of 2015, UBS tells investors.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here